Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

The Medical Cannabis and Wellness UCITS ETF – Accumulating (the “Fund”)  
A sub-fund of HANetf ICAV. Managed by HANetf Management Limited

Objectives and Investment Policy

The Fund seeks to track the price and yield performance, before fees and expenses, of the Medical Cannabis and Wellness Equity Index (the “Index”).

Index: The Index is governed by a published, rules-based methodology and is designed to measure the performance of an investable universe of publicly listed companies with significant business activities in the medical cannabis, hemp and cannabinoid (“CBD”) industry.

Eligibility: To be eligible for inclusion in the Index, companies must:
- have their primary listing on a regulated, major stock exchange that is part of the Developed and Emerging Markets as defined by the Solactive Country Classification; and
- meet the minimum market capitalisation and liquidity requirements.

The Index is reviewed and rebalanced on a quarterly basis.

Replication: The Fund will employ a “passive management” (or indexing) investment approach and will seek to employ a replication methodology, meaning insofar possible and practicable, it will invest in all of the securities comprising the Index.

Dealing: Shares of the Fund (“Shares”) are listed on one or more stock exchanges. Typically, only authorised participants (i.e. brokers) can purchase Shares from or sell Shares back to the Fund. Other investors can purchase and sell Shares on exchange on each day the relevant stock exchange is open.

Distribution policy: Income received by the Fund’s investments will not be distributed in respect of the Shares of this class. Instead will be accumulated and reinvested on behalf of the shareholders of the Fund.

Recommendation: This Fund may not be appropriate for short-term investment.

Currency: The base currency of the Fund is US Dollar.

For full investment objectives and policy details, please refer to the supplement to the prospectus for the Fund (the “Supplement”).

Risk and Reward Profile

<table>
<thead>
<tr>
<th>Lower risk</th>
<th>Higher risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Typically lower rewards</td>
<td>Typically higher rewards</td>
</tr>
</tbody>
</table>

The categorisation above is not guaranteed to remain unchanged and may shift over time.

The lowest category (1) does not imply a risk-free investment.

The risk indicator was calculated incorporating simulated historical data and may not be a reliable indication of the future risk profile of the Fund.

The categorisation above (7) is due to the nature of the Fund’s investments and risk associated with those investments, including:

- The value of underlying securities can be affected by daily financial market movements. Other influential factors include political, economic news, company earnings and significant corporate events.
- There is no assurance that any appreciation in the value of investments will occur, or that the investment objective of the Fund will be achieved.
- Investment risk: Investment risk may be concentrated in specific sectors, countries, currencies or companies. This means that the Fund may be more sensitive to any localised economic, market, political or regulatory events.
- Medical Cannabis Sector Risk: If a company becomes delisted from an exchange due to non-compliance with the rules and policies of the exchange, the Investment Manager will use reasonable endeavours to remove the company from the Sub-Fund’s portfolio.
- US Federal Law Risk: The Fund and the companies in which it invests may be subject to a higher degree of regulatory oversight and regulatory action, which may include a restriction on the types of companies that the Fund may invest in at any time.
- Sectoral Investment Risk: Companies in the biotechnology and medical sectors may be subject government and insurance regulations considerations, patent considerations, intense competition, rapid technological change, obsolescence of products and/or services.
- Currency risk: The Fund invests in securities denominated in currencies other than its base currency. Changes in the exchange rates may adversely affect the performance of the Fund.
- Risks not covered by the indicator, but which are materially relevant to the Fund include:
- Tracking error risk: The Fund’s performance may not exactly track the Index. This can result from market fluctuations, changes in the composition of the Index, transaction costs, the costs of making changes to the Fund’s portfolio and other Fund expenses.
- Liquidity on secondary market risk: There can be no certainty that Shares can always be bought or sold on a stock exchange or
that the market price will reflect the NAV of the Fund.

• It may be difficult for the Fund to buy or sell certain investments in some market conditions. Consequently, the price obtained when the Fund buys or sells securities may compare adversely to the price under normal market conditions.

For a complete overview of all risks attached to this Fund, refer to the section entitled “Risk Factors” in the Supplement and the Prospectus.

Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

| One-off charges taken before or after you invest |  
| Entry charge | 0%* |
| Exit charge | 0%* |

| Charges taken from the Fund over a year |  
| Ongoing charges | 0.80%** |

| Charges taken from the Fund under certain specific conditions |  
| Performance fee | None |

* Authorised participants dealing directly with the Fund may pay an entry charge up to a maximum of 5% and an exit charge up to a maximum of 3%. The Fund is currently not exercising its entitlement to apply entry and exit charges.

As the Fund is an ETF, secondary market investors will not typically be able to deal directly with HANetf ICAV. Investors buying Shares on exchange will do so at market prices which will reflect broker fees and/or transactions charges and bid-ask spreads.

* Authorised participants dealing directly with the Fund will pay related transaction costs.

* For Investors dealing directly with the Fund, switching between sub-funds may incur a maximum switching charge of 3%.

** The ongoing charges may vary year on year. It excludes portfolio transaction costs, except in the case of an entry/exit charge paid by the Fund when buying or selling units in another investment fund.

Please see “General Charges and Expenses” and “Management Charges and Expenses” sections of the Prospectus and “Charges and Expenses” and “Key Information for Share Dealing” sections of the Supplement for further information about charges.

Past Performance

• There is insufficient data to provide a useful indication of past performance to investors.

Practical Information

Investment Manager: Penserra Capital Management LLC.


Administrator: BNY Mellon Fund Services (Ireland) DAC.

Further information: Copies of the Prospectus documentation and the latest financial statements are available free of charge from the Administrator. The Prospectus and financial statements are prepared for HANetf ICAV rather than separately for the Fund. Further information on the composition of the portfolio and information on the Index constituents is available at www.HANetf.com.

Remuneration Policy: Details of HANetf Management Limited’s remuneration policy, including a description of how remuneration and benefits are calculated and the identities of the persons responsible for awarding such remuneration/benefits, can be accessed from the following website: www.hanetf.com. A paper copy of these policy details is also available free of charge from HANetf Management Limited upon request.

Pricing information: The net asset value of the share class will be available during normal business hours every business day at the office of the Administrator and will be published daily on www.hanetf.com.

Switching: Switching of Shares between sub-funds of HANetf ICAV is not possible for investors who purchase shares on exchange. Switching may be available to authorised participants who deal directly with the Fund.

Segregated liability: The Fund is a sub-fund of HANetf ICAV, an umbrella Irish collective asset-management vehicle. Under Irish law the assets and liabilities of the Fund are segregated from other sub-funds within HANetf ICAV and the assets of the Fund will not be available to satisfy the liabilities of another fund of HANetf ICAV.

Taxation: HANetf ICAV is resident in Ireland for taxation purposes. Irish taxation legislation may impact on the personal tax position of an investor.

Liability statement: HANetf Management Limited may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus.

This Fund is authorised in Ireland and regulated by the Central Bank of Ireland. HANetf Management Limited is authorised in Ireland and regulated by the Central Bank of Ireland.
This key investor information is accurate as at 19 February 2020.